nach oben

World Journal of Urology

Erschienen in:

23.07.2016 | Topic Paper

Platinum-refractory germ cell tumors: an update on current treatment options and developments

verfasst von: Christoph Oing, Winfried H. Alsdorf, Gunhild von Amsberg, Karin Oechsle, Carsten Bokemeyer

Erschienen in: World Journal of Urology | Ausgabe 8/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

In general, 50 % up to 80 % of metastasized germ cell tumor patients can be cured by platinum-based chemotherapy. However, 3–5 % of patients will still die of platinum-refractory disease and new systemic treatment options are needed to improve treatment success in this difficult setting. This review aims to give an overview on treatment options and current developments in the field of platinum-refractory male germ cell tumors.

Methods

A comprehensive literature search was conducted searching PubMed, Medline, Cochrane and Embase to identify clinical trials regarding the treatment of platinum-refractory disease. ASCO, EAU and ESMO conference proceedings were searched to identify unpublished results of relevant trials. Comprehensive review papers were hand searched for additional references. Clinicaltrials.gov was checked for ongoing clinical trials in the field of platinum-refractory germ cell tumors.

Results

Outcome of platinum-refractory disease remains poor. Single-agents with reasonable activity are gemcitabine, oxaliplatin and paclitaxel, but complete remissions resulting in long-term survival could not be achieved. The triple-combination of gemcitabine, oxaliplatin and paclitaxel followed by resection of residual masses provides the best outcomes with objective responses in 51 % of patients and long-term survival in approximately 10–15 %. To date, no molecularly targeted agent has shown reasonable activity.

Conclusions

Treatment options for platinum-refractory disease are limited, but a small subset of patients may achieve long-term disease-free survival by multimodal treatment. The potential of novel targeted agents, i.e. by immune-checkpoint-inhibition remains to be defined.

Huyghe E, Plante P, Thonneau PF (2007) Testicular cancer variations in time and space in Europe. Eur Urol 51(3):621–628CrossRefPubMed

IGCCCG (1997) International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 15(2):594–603CrossRef

van Dijk MR, Steyerberg EW, Habbema JD (2006) Survival of non-seminomatous germ cell cancer patients according to the IGCC classification: an update based on meta-analysis. Eur J Cancer 42(7):820–826CrossRefPubMed

Horwich A, Shipley J, Huddart R (2006) Testicular germ-cell cancer. Lancet 367(9512):754–765CrossRefPubMed

Beyer J, Kramar A, Mandanas R, Linkesch W, Greinix A, Droz JP, Pico JL, Diehl A, Bokemeyer C, Schmoll HJ, Nichols CR, Einhorn LH, Siegert W (1996) High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol 14(10):2638–2645CrossRefPubMed

Lorch A, Beyer J, Bascoul-Mollevi C, Kramar A, Einhorn LH, Necchi A, Massard C, De Giorgi U, Flechon A, Margolin KA, Lotz JP, Germa Lluch JR, Powles T, Kollmannsberger CK, International Prognostic Factors Study G (2010) Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol 28(33):4906–4911CrossRefPubMed

Einhorn LH (1990) Treatment of testicular cancer: a new and improved model. J Clin Oncol 8(11):1777–1781CrossRefPubMed

Gandaglia G, Becker A, Trinh QD, Abdollah F, Schiffmann J, Roghmann F, Tian Z, Montorsi F, Briganti A, Karakiewicz PI, Sun M (2014) Long-term survival in patients with germ cell testicular cancer: a population-based competing-risks regression analysis. Eur J Surg Oncol 40(1):103–112CrossRefPubMed

O’Carrigan B, Grimison P (2015) Current chemotherapeutic approaches for recurrent or refractory germ cell tumors. Urol Oncol 33(8):343–354CrossRefPubMed

10.

Oechsle K, Kollmannsberger C, Honecker F, Mayer F, Waller CF, Hartmann JT, Boehlke I, Bokemeyer C, German Testicular Cancer Study G (2011) Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumors. Eur Urol 60(4):850–855CrossRefPubMed

11.

Bokemeyer C, Oechsle K, Honecker F, Mayer F, Hartmann JT, Waller CF, Bohlke I, Kollmannsberger C, German Testicular Cancer Study G (2008) Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group. Ann Oncol 19(3):448–453CrossRefPubMed

12.

Garraway LA, Verweij J, Ballman KV (2013) Precision oncology: an overview. J Clin Oncol 31(15):1803–1805CrossRefPubMed

13.

Squillante CM, Vaughn DJ (2015) Targeted therapies in germ cell tumors. Urol Oncol 33(8):363–369CrossRefPubMed

14.

Porcu P, Bhatia S, Sharma M, Einhorn LH (2000) Results of treatment after relapse from high-dose chemotherapy in germ cell tumors. J Clin Oncol 18(6):1181–1186CrossRefPubMed

15.

Kollmannsberger C, Honecker F, Bokemeyer C (2008) Pharmacotherapy of relapsed metastatic testicular cancer. Expert Opin Pharmacother 9(13):2259–2272CrossRefPubMed

16.

Sadeghi S, Quinn D, Tsao-Wei D, Hamid O, Hu J, Schuckman A, Daneshmand S, Groshen S, Raghavan D, Dorff T (2013) Phase II study of gemcitabine, oxaliplatin, and paclitaxel (GOT) on a 2-weekly schedule in patients (pts) with refractory germ cell tumor (rGCT): final results. J Clin Oncol 31(Suppl); abstr 4531

17.

Necchi A, Nicolai N, Mariani L, Lo Vullo S, Giannatempo P, Raggi D, Fare E, Piva L, Biasoni D, Catanzaro M, Torelli T, Stagni S, Milani A, Gianni AM, Salvioni R (2014) Combination of paclitaxel, cisplatin, and gemcitabine (TPG) for multiple relapses or platinum-resistant germ cell tumors: long-term outcomes. Clin Genitourin Cancer 12(1):63–69CrossRefPubMed

18.

Zaffaroni N, Fiorentini G, De Giorgi U (2001) Hyperthermia and hypoxia: new developments in anticancer chemotherapy. Eur J Surg Oncol 27(4):340–342CrossRefPubMed

19.

Wessalowski R, Schneider DT, Mils O, Friemann V, Kyrillopoulou O, Schaper J, Matuschek C, Rothe K, Leuschner I, Willers R, Schonberger S, Gobel U, Calaminus G, group Ms (2013) Regional deep hyperthermia for salvage treatment of children and adolescents with refractory or recurrent non-testicular malignant germ-cell tumours: an open-label, non-randomised, single-institution, phase 2 study. Lancet Oncol 14(9):843–852CrossRefPubMed

20.

Lorch A, Bascoul-Mollevi C, Kramar A, Einhorn L, Necchi A, Massard C, De Giorgi U, Flechon A, Margolin K, Lotz JP, Germa-Lluch JR, Powles T, Kollmannsberger C, Beyer J (2011) Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol 29(16):2178–2184CrossRefPubMed

21.

Feldman DR, Sheinfeld J, Bajorin DF, Fischer P, Turkula S, Ishill N, Patil S, Bains M, Reich LM, Bosl GJ, Motzer RJ (2010) TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J Clin Oncol 28(10):1706–1713CrossRefPubMedPubMedCentral

22.

Lorch A, Neubauer A, Hackenthal M, Dieing A, Hartmann JT, Rick O, Bokemeyer C, Beyer J (2010) High-dose chemotherapy (HDCT) as second-salvage treatment in patients with multiple relapsed or refractory germ-cell tumors. Ann Oncol 21(4):820–825CrossRefPubMed

23.

Koster R, van Vugt MA, Timmer-Bosscha H, Gietema JA, de Jong S (2013) Unravelling mechanisms of cisplatin sensitivity and resistance in testicular cancer. Expert Rev Mol Med 15:e12CrossRefPubMed

24.

Feldman DR, Bagrodia A, Lee B, Lee W, Al-Ahmadie H, Cha EK, Sfakianos J, Iyer G, Zabor EG, Ostrovnaya I, Eng J, Arcila ME, Chaganti RSK, Schultz N, Reuter VE, Bains M, Sheinfeld J, Carver BS, Bosl GJ, Solit DB (2015) Association of genomic alterations with cisplatin resistance (cisR) in advanced germ cell tumors (aGCT). J Clin Oncol 33(Suppl):abstr 4510

25.

Jacobsen C, Honecker F (2015) Cisplatin resistance in germ cell tumours: models and mechanisms. Andrology 3(1):111–121CrossRefPubMed

26.

Feldman DR, Iyer G, Van Alstine L, Patil S, Al-Ahmadie H, Reuter VE, Bosl GJ, Chaganti RS, Solit DB (2014) Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors. Clin Cancer Res 20(14):3712–3720CrossRefPubMed

27.

Oing C, Bokemeyer C, Russell K, Millis SZ, Bender R, Gatalica Z, Voss A (2015) Molecular profiling of cisplatin-resistant testicular germ cell tumors. Oncol Res Treat 38(Suppl. 5):168–169 (abstr V556)

28.

Juliachs M, Munoz C, Moutinho CA, Vidal A, Condom E, Esteller M, Graupera M, Casanovas O, Germa JR, Villanueva A, Vinals F (2014) The PDGFRbeta–AKT pathway contributes to CDDP-acquired resistance in testicular germ cell tumors. Clin Cancer Res 20(3):658–667CrossRefPubMed

29.

Fukuda S, Shirahama T, Imazono Y, Tsushima T, Ohmori H, Kayajima T, Take S, Nishiyama K, Yonezawa S, Akiba S, Akiyama S, Ohi Y (1999) Expression of vascular endothelial growth factor in patients with testicular germ cell tumors as an indicator of metastatic disease. Cancer 85(6):1323–1330CrossRefPubMed

30.

Laplante M, Sabatini DM (2012) mTOR signaling in growth control and disease. Cell 149(2):274–293CrossRefPubMedPubMedCentral

31.

Cutcutache I, Suzuki Y, Tan IB, Ramgopal S, Zhang S, Ramnarayanan K, Gan A, Lee HH, Tay ST, Ooi A, Ong CK, Bolthouse JT, Lane BR, Anema JG, Kahnoski RJ, Tan P, Teh BT, Rozen SG (2015) Exome-wide sequencing shows low mutation rates and identifies novel mutated genes in seminomas. Eur Urol 68(1):77–83CrossRefPubMed

32.

Honecker F, Wermann H, Mayer F, Gillis AJ, Stoop H, van Gurp RJ, Oechsle K, Steyerberg E, Hartmann JT, Dinjens WN, Oosterhuis JW, Bokemeyer C, Looijenga LH (2009) Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors. J Clin Oncol 27(13):2129–2136CrossRefPubMed

33.

Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X (2015) Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med 21(1):24–33CrossRefPubMed

34.

Frankhauser CD, Fontecedro AC, Beyer J, Tischler V, Sulser T, Moch H, Bode PK (2015) Frequent expression of PD-L1 in testicular germ cell tumors. J Clin Oncol 33

35.

Gold EJ, Bosl GJ, Itri LM (1984) Phase II trial of 13-cis-retinoic acid in patients with advanced nonseminomatous germ cell tumors. Cancer Treat Rep 68(10):1287–1288PubMed

36.

Moasser MM, Motzer RJ, Khoo KS, Lyn P, Murphy BA, Bosl GJ, Dmitrovsky E (1995) All-trans retinoic acid for treating germ cell tumors. In vitro activity and results of a phase II trial. Cancer 76(4):680–686CrossRefPubMed

37.

Beer TM, Tangen CM, Nichols CR, Margolin KA, Dreicer R, Stephenson WT, Quinn DI, Raghavan D, Crawford ED (2006) Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies. Cancer 106(12):2624–2629CrossRefPubMed

38.

Schmidt BA, Rose A, Steinhoff C, Strohmeyer T, Hartmann M, Ackermann R (2001) Up-regulation of cyclin-dependent kinase 4/cyclin D2 expression but down-regulation of cyclin-dependent kinase 2/cyclin E in testicular germ cell tumors. Cancer Res 61(10):4214–4221PubMed

39.

Strohmeyer T, Reissmann P, Cordon-Cardo C, Hartmann M, Ackermann R, Slamon D (1991) Correlation between retinoblastoma gene expression and differentiation in human testicular tumors. Proc Natl Acad Sci USA 88(15):6662–6666CrossRefPubMedPubMedCentral

40.

Vaughn DJ, Flaherty K, Lal P, Gallagher M, O’Dwyer P, Wilner K, Chen I, Schwartz G (2009) Treatment of growing teratoma syndrome. N Engl J Med 360(4):423–424CrossRefPubMed

41.

Vaughn DJ, Hwang WT, Lal P, Rosen MA, Gallagher M, O’Dwyer PJ (2015) Phase 2 trial of the cyclin-dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein-expressing germ cell tumors. Cancer 121(9):1463–1468CrossRefPubMed

42.

Narayan V, Hwang WT, Lal P, Rosen MA, Gallagher M, O’Dwyer PJ, Vaughn DJ (2016) Cyclin-dependent Kinase 4/6 Inhibition for the treatment of unresectable mature teratoma: long-term follow-up of a phase II study. Clin Genitourin Cancer

43.

Beyrouthy MJ, Garner KM, Hever MP, Freemantle SJ, Eastman A, Dmitrovsky E, Spinella MJ (2009) High DNA methyltransferase 3B expression mediates 5-aza-deoxycytidine hypersensitivity in testicular germ cell tumors. Cancer Res 69(24):9360–9366CrossRefPubMedPubMedCentral

44.

Roth BJ, Elson P, Sledge GW Jr, Einhorn LH, Trump DL (1993) 5-Azacytidine (NSC 102816) in refractory germ cell tumors. A phase II trial of the Eastern Cooperative Oncology Group. Investig New Drugs 11(2–3):201–202CrossRef

45.

Clavel M, Monfardini S, Fossa S, Smyth J, Renard J, Kaye SB (1992) 5-Aza-2′-deoxycytidine (NSC 127716) in non-seminomatous testicular cancer. Phase II from the EORTC Early Clinical Trials Cooperative Group and Genito-Urinary Group. Ann Oncol 3(5):399–400CrossRefPubMed

46.

Rick O, Braun T, Siegert W, Beyer J (2006) Activity of thalidomide in patients with platinum-refractory germ-cell tumours. Eur J Cancer 42(12):1775–1779CrossRefPubMed

47.

Oechsle K, Bokemeyer C, Honecker F (2010) Lenalidomide in patients with cisplatin-refractory and multiply relapsed germ cell tumors. J Cancer Res Clin Oncol 136(1):165–167CrossRefPubMed

48.

Jain A, Brames MJ, Vaughn D, Einhorn L (2011) Phase II clinical trial of oxaliplatin and bevacizumab in refractory metastatic germ cell tumors (GCT). J Clin Oncol 29(Suppl):abstr 4579

49.

Nieto Y, Tu SM, Bassett R, Jones RB, Gulbis AM, Tannir N, Kingham A, Ledesma C, Margolin K, Holmberg L, Champlin R, Pagliaro L (2015) Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors. Ann Oncol 26(10):2125–2132CrossRefPubMedPubMedCentral

50.

Einhorn LH, Brames MJ, Heinrich MC, Corless CL, Madani A (2006) Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT. Am J Clin Oncol 29(1):12–13CrossRefPubMed

51.

Oechsle K, Honecker F, Cheng T, Mayer F, Czaykowski P, Winquist E, Wood L, Fenner M, Glaesener S, Hartmann JT, Chi K, Bokemeyer C, Kollmannsberger C (2011) Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study. Ann Oncol 22(12):2654–2660CrossRefPubMed

52.

Feldman DR, Turkula S, Ginsberg MS, Ishill N, Patil S, Carousso M, Bosl GJ, Motzer RJ (2010) Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors. Investig New Drugs 28(4):523–528CrossRef

53.

Giannatempo P, Nicolai N, Farè E, Raggi D, Piva L, Biasoni D, Catanzaro M, Torelli T, Stagni S, Maffezzini M, Crestani A, Togliardi E, Salvioni R, Gianni AM, Necchi A (2014) Activity of pazopanib in chemo-resistant patients with germ cell tumors (GCT): first results of the open-label, single-group, phase II PAZOTEST-01 trial. J Clin Oncol 32(Suppl 4):abstr 376

54.

Skoneczna IA, Natorska U, Tacikowska M, Kraszewska E, Kotowicz B, Fuksiewicz M, Rogowski WW, Federowicz I, Poniatowska G, Chaladaj-Kujawska A, Michalski W (2014) Sorafenib monotherapy in patients with inoperable/recurrent germ cell tumors (GCT) refractory to chemotherapy: Phase II study. J Clin Oncol 32(Suppl 4):abstr 367

55.

Steinemann G, Jacobsen C, Gerwing M, Hauschild J, von Amsberg G, Hopfner M, Nitzsche B, Honecker F (2015) Activity of nintedanib in germ cell tumors. Anticancer Drugs

56.

Motzer RJ, Dmitrovsky E, Miller WH Jr, Tong WP, Bajorin DF, Scher HI, Bost GJ (1993) Suramin for germ cell tumors. In vitro growth inhibition and results of a phase II trial. Cancer 72(11):3313–3317CrossRefPubMed

57.

Mego M, Svetlovska D, Miskovska V, Obertova J, Palacka P, Rajec J, Sycova-Mila Z, Chovanec M, Rejlekova K, Zuzak P, Ondrus D, Spanik S, Reckova M, Mardiak J (2016) Phase II study of everolimus in refractory testicular germ cell tumors. Urol Oncol 34(3):122CrossRefPubMed

58.

Necchi A, Magazzu D, Anichini A, Raggi D, Giannatempo P, Nicolai N, Colecchia M, Paolini B, Coradeshi E, Tassi E, Grazia G, Mortarini R, Calareso G, Togliardi E, Crippa F, Salvioni R, Gianni AM, Valagussa P (2016) An open-label, single-group, phase 2 study of brentuximab vedotin as salvage therapy for males with relapsed germ-cell tumors (GCT): Results at the end of first stage (FM12GCT01). J Clin Oncol 34(Suppl 2S):abstr 480

59.

Rick O, Bokemeyer C, Weinknecht S, Schirren J, Pottek T, Hartmann JT, Braun T, Rachud B, Weissbach L, Hartmann M, Siegert W, Beyer J (2004) Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell cancer. J Clin Oncol 22(18):3713–3719CrossRefPubMed

60.

Beck SD, Foster RS, Bihrle R, Einhorn LH, Donohue JP (2005) Pathologic findings and therapeutic outcome of desperation post-chemotherapy retroperitoneal lymph node dissection in advanced germ cell cancer. Urol Oncol 23(6):423–430CrossRefPubMed

61.

Masterson TA, Shayegan B, Carver BS, Bajorin DF, Feldman DR, Motzer RJ, Bosl GJ, Sheinfeld J (2012) Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer. Urology 79(1):156–159CrossRefPubMed

62.

Daneshmand S, Albers P, Fossa SD, Heidenreich A, Kollmannsberger C, Krege S, Nichols C, Oldenburg J, Wood L (2012) Contemporary management of postchemotherapy testis cancer. Eur Urol 62(5):867–876CrossRefPubMed

63.

Coogan CL, Foster RS, Rowland RG, Bihrle R, Smith ER Jr, Einhorn LH, Roth BJ, Donohue JP (1997) Postchemotherapy retroperitoneal lymph node dissection is effective therapy in selected patients with elevated tumor markers after primary chemotherapy alone. Urology 50(6):957–962CrossRefPubMed

64.

Albers P, Ganz A, Hannig E, Miersch WD, Muller SC (2000) Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers. J Urol 164(2):381–384CrossRefPubMed

65.

Heidenreich A, Thuer D, Polyakov S (2008) Postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumours of the testis. Eur Urol 53(2):260–272CrossRefPubMed

66.

Beck SD, Foster RS, Bihrle R, Einhorn LH, Donohue JP (2005) Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol 23(25):6149–6156. doi:10.1200/JCO.2005.11.684 CrossRefPubMed

67.

Miller JC, Einhorn LH (1990) Phase II study of daily oral etoposide in refractory germ cell tumors. Semin Oncol 17(1 Suppl 2):36–39PubMed

Titel: Platinum-refractory germ cell tumors: an update on current treatment options and developments
verfasst von: Christoph Oing
Winfried H. Alsdorf
Gunhild von Amsberg
Karin Oechsle
Carsten Bokemeyer
Publikationsdatum: 23.07.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: World Journal of Urology / Ausgabe 8/2017
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-016-1898-z

Neu im Fachgebiet Urologie

25.04.2024 | Nierenkarzinom | Nachrichten

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Platinum-refractory germ cell tumors: an update on current treatment options and developments

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Urologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2017

High-dose chemotherapy as salvage treatment in germ-cell cancer: when, in whom and how

Improved decision making in intermediate-risk prostate cancer: a multicenter study on pathologic and oncologic outcomes after radical prostatectomy

Residual stones after percutaneous nephrolithotomy: comparison of intraoperative assessment and postoperative non-contrast computerized tomography

Simulated physiological stretch increases expression of extracellular matrix proteins in human bladder smooth muscle cells via integrin α4/αv-FAK-ERK1/2 signaling pathway

Randomized, double-blind, placebo-controlled trial to compare solifenacin versus trospium chloride in the relief of double-J stent-related symptoms

Contralateral biopsies in patients with testicular germ cell tumours: What is the rationale?

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Urologie